Redefining susceptibility in practice : clinical and resistance outcomes of the EUCAST ‘I’ category for wild-type Pseudomonas aeruginosa
Infection · 2026-10 · 54 (5) · 2633-2641
DOI: 10.1007/s15010-026-02893-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection, online erschienen am 13.08.2026. Verfasst von Melike Törüyenler Coşkunpınar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Bacterial Agents, Pseudomonas Infections, Drug Resistance, Bacterial. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The 2019 EUCAST redefinition of the "susceptible, increased exposure" (I) category aimed to optimize antimicrobial therapy and reduce unnecessary carbapenem prescribing. However, concerns remain that misinterpretation may promote carbapenem overuse. We evaluated clinical and resistance outcomes associated with I-category agents compared to meropenem in wild-type (WT) Pseudomonas aeruginosa infections. METHODS: In this retrospective cohort study, adult inpatients with microbiologically confirmed WT P. aeruginosa infections between January 2020 and March 2024 were included. Eligible isolates were susceptible to meropenem and categorized as "I" to at least one antipseudomonal agent (piperacillin-tazobactam, ceftazidime, cefepime, or ciprofloxacin). Patients received either I-category agents or meropenem as definitive therapy. Primary outcomes were clinical failure and all-cause mortality. Secondary outcomes included emergence of carbapenem-resistant microorganisms within one year. RESULTS: A total of 411 patients were included (I group n = 152; meropenem group n = 259). Clinical failure (9.2% vs. 6.9%, p = 0.409) and mortality at all time points were comparable between groups. However, meropenem use was independently associated with the development of carbapenem-resistant P. aeruginosa (CRPA) within one year (OR 2.38, 95% CI 1.02-5.57; p = 0.046). In contrast, emergence of any carbapenem-resistant organism was associated with prior antibiotic exposure and disease severity, but not treatment group. CONCLUSION: In WT P. aeruginosa infections, treatment with EUCAST I-category agents achieved clinical outcomes comparable to meropenem. However, meropenem use was independently associated with subsequent CRPA isolation. These findings support carbapenem-sparing strategies and highlight the long-term resistance implications of antimicrobial selection following the EUCAST redefinition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, Turkey. elifmozturk@gmail.com.
ORCID-Profile: Güle Çınar, Pelin Çakmak
Zitieren
APA
Törüyenler Coşkunpınar, M., Sarıcaoğlu, E. M., Çınar, G., Akdemir, İ., Gülten, E., Çakmak, P., & Azap, A. (2026). Redefining susceptibility in practice : clinical and resistance outcomes of the EUCAST ‘I’ category for wild-type Pseudomonas aeruginosa. Infection, 54(5), 2633-2641. https://doi.org/10.1007/s15010-026-02893-w
Vancouver
Törüyenler Coşkunpınar M, Sarıcaoğlu EM, Çınar G, Akdemir İ, Gülten E, Çakmak P, et al. Redefining susceptibility in practice : clinical and resistance outcomes of the EUCAST ‘I’ category for wild-type Pseudomonas aeruginosa. Infection. 2026;54(5):2633-2641. doi:10.1007/s15010-026-02893-w
BibTeX
@article{TryenlerCokunpnar2026,
author = {Törüyenler Coşkunpınar, Melike and Sarıcaoğlu, Elif M and Çınar, Güle and Akdemir, İrem and Gülten, Ezgi and Çakmak, Pelin and Azap, Alpay},
title = {Redefining susceptibility in practice : clinical and resistance outcomes of the EUCAST ‘I’ category for wild-type Pseudomonas aeruginosa},
journal = {Infection},
year = {2026},
volume = {54},
number = {5},
pages = {2633--2641},
doi = {10.1007/s15010-026-02893-w}
}
EUVIMED